Cargando…
Pneumocystis jirovecii pneumonia in non-Hodgkin’s lymphoma after rituximab-based chemotherapy: a case series
BACKGROUND: The incidence of Pneumocystis jirovecii pneumonia (PCP) has been increasing in patients with hematologic malignancies due to the use of glucocorticoid therapy and immunosuppressive medication. The reports of PCP in non-Hodgkin’s lymphoma (NHL) after rituximab-based chemotherapy are still...
Autores principales: | Zhang, Qianying, Han, Liang, Lin, Yuanyuan, Sun, Xiaohong, Ye, Haige, Qian, Honglan, Sun, Lan, Jiang, Songfu, Liang, Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372200/ https://www.ncbi.nlm.nih.gov/pubmed/35966314 http://dx.doi.org/10.21037/tcr-22-1216 |
Ejemplares similares
-
Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients
por: Wei, Kai-Che, et al.
Publicado: (2018) -
P1565: INCIDENCE OF PNEUMOCYSTIS JIROVECII PNEUMONIA IN PATIENTS WITH B-LINEAGE LYMPHOMA RECEIVING CHEMOTHERAPY CONTAINING RITUXIMAB
por: Liang, Xiping Xiping, et al.
Publicado: (2023) -
Pneumocystis jirovecii Pneumonia Prophylaxis for Cancer Patients during Chemotherapy
por: Takeuchi, Kazuto, et al.
Publicado: (2021) -
Pneumocystis jirovecii pneumonia in developing countries
por: De Armas Rodríguez, Y., et al.
Publicado: (2011) -
Cryobiopsy for Pneumocystis jirovecii pneumonia secondary to adult T‐cell lymphoma/leukaemia
por: Kobe, Hiroshi, et al.
Publicado: (2021)